Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC Adult Leukaemia Working Party

Research output: Contribution to journalArticlepeer-review

Standard

Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC Adult Leukaemia Working Party. / Langabeer, S E; Walker, H; Gale, R E; Wheatley, K; Burnett, A K; Goldstone, A H; Linch, D C.

In: British Journal of Haematology, Vol. 96, No. 4, 03.1997, p. 736-9.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{00d036a7bcd3421791a6c92ae7f0bcd3,
title = "Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC Adult Leukaemia Working Party",
abstract = "It has been established that cytogenetic findings at diagnosis of acute myeloid leukaemia (AML) are a powerful prognostic indicator. Patients who have the inv(16)(p13q22), closely associated with the FAB subtype M4Eo. are deemed to have good-risk disease. This subtle translocation may be difficult to detect in poor-quality metaphase preparations and if missed could lead to the incorrect assignment of risk group and influence further treatment strategies. We studied 321 patients with AML at diagnosis for the presence of inv(16)(p13q22) and CBF beta/MYH11 fusion transcripts by cytogenetic and RT-PCR techniques respectively. Karyotypic analysis detected 21 cases of inv(16) (p13q22), all of which were PCR positive. A further 12 cases were detected at the molecular level only, in FAB types other than M4Eo. The observed frequencies of CBF beta/MYH11 fusion transcripts in our study have been adjusted for the reported incidence of each FAB subtype and we calculate that 10.1% of all new cases of AMLs have molecular evidence of inv(16)(p13q22). only half of which are of the M4Eo subtype. We conclude that molecular screening for the presence of CBF beta/MYH11 fusion transcripts should be mandatory in all case of AML at diagnosis.",
keywords = "Adolescent, Adult, Aged, Chromosome Inversion, Chromosomes, Human, Pair 16, Genetic Testing, Humans, Leukemia, Myeloid, Acute, Middle Aged, Oncogene Proteins, Fusion, Polymerase Chain Reaction, Transcription, Genetic, Treatment Outcome",
author = "Langabeer, {S E} and H Walker and Gale, {R E} and K Wheatley and Burnett, {A K} and Goldstone, {A H} and Linch, {D C}",
year = "1997",
month = mar,
language = "English",
volume = "96",
pages = "736--9",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley",
number = "4",

}

RIS

TY - JOUR

T1 - Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC Adult Leukaemia Working Party

AU - Langabeer, S E

AU - Walker, H

AU - Gale, R E

AU - Wheatley, K

AU - Burnett, A K

AU - Goldstone, A H

AU - Linch, D C

PY - 1997/3

Y1 - 1997/3

N2 - It has been established that cytogenetic findings at diagnosis of acute myeloid leukaemia (AML) are a powerful prognostic indicator. Patients who have the inv(16)(p13q22), closely associated with the FAB subtype M4Eo. are deemed to have good-risk disease. This subtle translocation may be difficult to detect in poor-quality metaphase preparations and if missed could lead to the incorrect assignment of risk group and influence further treatment strategies. We studied 321 patients with AML at diagnosis for the presence of inv(16)(p13q22) and CBF beta/MYH11 fusion transcripts by cytogenetic and RT-PCR techniques respectively. Karyotypic analysis detected 21 cases of inv(16) (p13q22), all of which were PCR positive. A further 12 cases were detected at the molecular level only, in FAB types other than M4Eo. The observed frequencies of CBF beta/MYH11 fusion transcripts in our study have been adjusted for the reported incidence of each FAB subtype and we calculate that 10.1% of all new cases of AMLs have molecular evidence of inv(16)(p13q22). only half of which are of the M4Eo subtype. We conclude that molecular screening for the presence of CBF beta/MYH11 fusion transcripts should be mandatory in all case of AML at diagnosis.

AB - It has been established that cytogenetic findings at diagnosis of acute myeloid leukaemia (AML) are a powerful prognostic indicator. Patients who have the inv(16)(p13q22), closely associated with the FAB subtype M4Eo. are deemed to have good-risk disease. This subtle translocation may be difficult to detect in poor-quality metaphase preparations and if missed could lead to the incorrect assignment of risk group and influence further treatment strategies. We studied 321 patients with AML at diagnosis for the presence of inv(16)(p13q22) and CBF beta/MYH11 fusion transcripts by cytogenetic and RT-PCR techniques respectively. Karyotypic analysis detected 21 cases of inv(16) (p13q22), all of which were PCR positive. A further 12 cases were detected at the molecular level only, in FAB types other than M4Eo. The observed frequencies of CBF beta/MYH11 fusion transcripts in our study have been adjusted for the reported incidence of each FAB subtype and we calculate that 10.1% of all new cases of AMLs have molecular evidence of inv(16)(p13q22). only half of which are of the M4Eo subtype. We conclude that molecular screening for the presence of CBF beta/MYH11 fusion transcripts should be mandatory in all case of AML at diagnosis.

KW - Adolescent

KW - Adult

KW - Aged

KW - Chromosome Inversion

KW - Chromosomes, Human, Pair 16

KW - Genetic Testing

KW - Humans

KW - Leukemia, Myeloid, Acute

KW - Middle Aged

KW - Oncogene Proteins, Fusion

KW - Polymerase Chain Reaction

KW - Transcription, Genetic

KW - Treatment Outcome

M3 - Article

C2 - 9074414

VL - 96

SP - 736

EP - 739

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -